Rare Disease Consultations™: Uncommon Presentations of hATTR Amyloidosis: Coordinating Care Between the Cardiologist and Neurologist

Released On
September 10, 2020

Expires On
September 10, 2021

Media Type

Completion Time
90 minutes

Cardiology, Critical Care, Gastroenterology, Nephrology, Neurology, Ophthalmology, Pathology, Primary Care, Pulmonology

Arthritis, Cardiovascular Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Physicians’ Education Resource®, LLC.

Supported by an educational grants from Akcea Therapeutics, Inc. and Alnylam Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)
  • Nurses — 1.50 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is primarily directed toward neurologists, cardiologists, and specialty NPs and PAs. Additional HCPs who have the opportunity to recognize red-flag symptoms of hATTR amyloidosis will be invited to participate such as critical care specialists, primary care physicians, ophthalmologists, nephrologists, pulmonologists, gastroenterologists, pathologists, NPs, PAs, and nurses.

Program Overview

This Rare Disease Consultations™ activity is a video-based program in which two experts discuss the management of hereditary transthyretin-mediated (hATTR) amyloidosis. In this activity, the faculty will focus on current and emerging therapeutic strategies for managing hATTR amyloidosis and will discuss patient cases. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of hATTR amyloidosis and to improve outcomes for patients with this disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize the varied phenotypic presentation and underlying genotypes of hATTR amyloidosis
  • Identify red-flag symptoms and the role of genetic testing methods in accurately diagnosing hATTR amyloidosis
  • Evaluate the efficacy and safety of current and emerging agents for the treatment of patients with hATTR amyloidosis
  • Describe best practices for effective communication and coordination between cardiologists and neurologists to optimize patient outcomes


Rodney H. Falk, MD

Associate Professor, Harvard Medical School
Brigham and Women's Hospital
Division of Cardiovascular Medicine
Boston, MA

Sami L. Khella, MD

Professor and Chief of Neurology
Penn Presbyterian Medical Center
University of Pennsylvania School of Medicine
Philadelphia, PA

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hour.

Disclosures of Conflicts of Interest

Rodney H. Falk, MD

  • Grant Research Support: Pfizer, Akcea, Ionis: Consultant: Pfizer, Akcea, Ionis

Sami L. Khella, MD has no relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit


  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.


Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.


As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.